导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.68% | 2041/4773 |
| 近一周 | -2.48% | 2311/5462 |
| 近一月 | -4.11% | 2222/5421 |
| 近一季 | -7.73% | 2513/5209 |
| 近半年 | -6.71% | 3129/4920 |
| 近一年 | 5.61% | 1573/4366 |
| 近两年 | 68.28% | 1009/2954 |
| 近三年 | 36.80% | 810/2253 |
| 成立以来 | 56.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.23% 1599/4961 |
16.00% 1612/5312 |
- - |
- - |
| 2025 | 33.17% 1131/4813 |
3.10% 1193/3635 |
4.75% 702/4076 |
19.82% 2089/4524 |
2.91% 814/4813 |
| 2024 | 7.73% 1627/3463 |
-0.56% 1125/2808 |
-3.86% 1425/3014 |
13.25% 2209/3129 |
-0.49% 1441/3463 |
| 2023 | -5.82% 782/2656 |
8.16% 489/2280 |
-3.82% 917/2385 |
-4.20% 1087/2515 |
-5.49% 1370/2655 |
| 2022 | -15.20% 411/2207 |
-9.44% 328/1919 |
4.24% 1030/2016 |
-8.65% 216/2113 |
-1.65% 1722/2208 |
| 2021 | 4.38% 582/1822 |
-3.30% 797/1255 |
10.20% 488/1330 |
-2.38% 570/1466 |
0.35% 1130/1822 |
| 2020 | 29.09% 548/1250 |
-3.38% 299/1028 |
19.01% 315/1067 |
7.87% 755/1164 |
4.07% 872/1184 |
| 2019 | 24.23% 623/1092 |
26.14% 424/754 |
-9.76% 688/804 |
1.98% 336/850 |
7.02% 502/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.92% 381/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华宝中证500增强C VS. 长安沪深300非周期A(740101) |